ACM
GPCR icon

ACT Capital Management’s Structure Therapeutics GPCR Stock Holding History

ACT Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,500
Closed -$2.68M – 64
2025
Q4 		$2.68M Buy
+38,500
New +$1.57M 2.17% 13

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ACT Capital Management's GPCR Position: Q1 2026 in Review

ACT Capital Management sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 38,500 shares — an estimated $2.68M sold.

ACT Capital Management first reported a position in GPCR in Q4 2025 and held it in 1 quarter. The position peaked at $2.68M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • ACT Capital Management reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ACT Capital Management sold 38,500 Structure Therapeutics shares in Q1 2026, an estimated $2.68M.
  • ACT Capital Management first reported a position in Structure Therapeutics in Q4 2025 and held it in 1 quarter.
  • ACT Capital Management's Structure Therapeutics position peaked at $2.68M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on ACT Capital Management's 13F filing for Q1 2026, filed 8 May 2026.